Abbott Explains Continuous Glucose Monitoring (CGM) Technology
Abbott Laboratories has released a guide clarifying the basics of continuous glucose monitoring (CGM) and its benefits for people with diabetes. The company details how its FreeStyle Libre portfolio aids in tracking blood glucose levels.
Medical device company Abbott Laboratories has issued a release aimed at educating the public about continuous glucose monitoring (CGM) technology and its utility for individuals managing diabetes.
The release outlines how CGM systems, such as Abbott's FreeStyle Libre portfolio, provide real-time tracking of glucose levels throughout the day and night. This information helps users and their healthcare providers understand the impact of food and activity on glucose levels and anticipate potential highs or lows.
Abbott's FreeStyle Libre sensors, ranging in size from two stacked quarters to a US penny, measure glucose levels beneath the skin and transmit data to a reader or compatible smartphone. The company highlights the FreeStyle Libre 3 sensor as the world's smallest, thinnest, and most accurate 14-day glucose sensor, offering real-time readings without the need for scanning. Additionally, the FreeStyle Libre 2 Plus sensor can connect to insulin pumps for automated insulin delivery.
Continuous monitoring offers an advantage over traditional fingerstick blood glucose tests by providing ongoing trends and directionality of glucose levels, allowing for more informed and timely management decisions. The technology is presented as a tool to help manage serious health impacts associated with hypoglycemia and hyperglycemia.
Abbott aims to empower individuals with diabetes to make informed health choices. Data from the devices can be shared with loved ones or healthcare professionals to support comprehensive diabetes care.